Silexion Therapeutics Corp (SLXN)

$7.48 +0.24 (3.31%)
Market Cap 4.20M
Revenue (ttm) 0.00
Net Income (ttm) -16.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.15
Volume 13,900
Avg Vol 82,937
Day's Range N/A - N/A
Shares Out 580,000.00
Stochastic %K 8%
Beta 0.08
Analysts Strong Sell
Price Target $74.96

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center, Jerusalem, Israel
JdNews
JdNews Aug. 19 at 1:24 AM
$SLXN Still here. Dead as a zombie movie. But, someday, someday will rebound with news. Sell the high as it did hit 8.60$. But with their tumor news and 2026 countdown. It’s a nothing burger, until we get more news. From this level it’s still bullish as it hasn’t past 7$.
0 · Reply
athebeast
athebeast Aug. 18 at 3:53 PM
$SLXN My favorite short. 😍
0 · Reply
JdNews
JdNews Aug. 13 at 5:02 AM
$SLXN These are the kind of stocks that will whiplash out of no where. No one’s watching it anymore. Til it breaks 100% again. Analyst PT 75$.
0 · Reply
JdNews
JdNews Aug. 13 at 4:43 AM
$SLXN This has news by 2026. Yes it’s far off. But, it has drug that could change everything for pancreatic cancer. It’s a waiting game here. Buy the low. 7s are the low. Wait keep buying. Sometimes, a stock that has RS but has news, can run again like crazy. This is an investment waiting on news.
0 · Reply
alphaonetrading
alphaonetrading Aug. 13 at 3:20 AM
$SLXN Wait for a dip to $2.63–$4.17 to buy, as the current $7.50 price exceeds the risk-adjusted valuation. Monitor catalysts (regulatory submissions, partnerships, phase two data in 2025–2026) and prepare for dilution from the ATM. Given the 5% success probability and financial risks, allocate a small portfolio portion and set a stop-loss (e.g., 20–30% below entry)
0 · Reply
Bentradez
Bentradez Aug. 12 at 12:15 PM
$SLXN please put out a PR 🥲
0 · Reply
woolpourpis69
woolpourpis69 Aug. 11 at 11:57 AM
$SLXN scam only down.. never
0 · Reply
rosie_o
rosie_o Aug. 8 at 9:27 PM
$SLXN I assume this is glitching going up $.68 after hours. Anyone else see this?
0 · Reply
JdNews
JdNews Aug. 8 at 6:26 PM
$CYCC $ABVE $BTOG $SLXN $WBUY Do you really not know the news here and why this is going crazy since squeeze?
1 · Reply
JdNews
JdNews Aug. 8 at 6:04 PM
$SLXN Man, I know alot of you lost money here. RS suck. You should never hold thru one. But, for initial buyers at 7$ low two days ago, this is money. Analyst says 75$ PT. They have pipelines of drug here. 2026 is the year. I know that’s a ways away. Gives it time to simmer. Still low float. Not as low as before. But, waiting here on news. $CYCC
0 · Reply
Latest News on SLXN
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 6 days ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 8:00 PM EDT - 18 days ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 31, 2025, 9:55 AM EDT - 18 days ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 16, 2025, 8:44 AM EDT - 4 weeks ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Jul 9, 2025, 8:30 AM EDT - 5 weeks ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 3 months ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 3 months ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 3 months ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 4 months ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 5 months ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 5 months ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 5 months ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 5 months ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 12:05 PM EST - 5 months ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 5 months ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 6 months ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 6 months ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 7 months ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 7 months ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 7 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 12:08 PM EST - 7 months ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 7 months ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jan 16, 2025, 8:51 AM EST - 7 months ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 7 months ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 7 months ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 7 months ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 8 months ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 9 months ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 9 months ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 11 months ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 9:25 AM EDT - 11 months ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 11 months ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

JdNews
JdNews Aug. 19 at 1:24 AM
$SLXN Still here. Dead as a zombie movie. But, someday, someday will rebound with news. Sell the high as it did hit 8.60$. But with their tumor news and 2026 countdown. It’s a nothing burger, until we get more news. From this level it’s still bullish as it hasn’t past 7$.
0 · Reply
athebeast
athebeast Aug. 18 at 3:53 PM
$SLXN My favorite short. 😍
0 · Reply
JdNews
JdNews Aug. 13 at 5:02 AM
$SLXN These are the kind of stocks that will whiplash out of no where. No one’s watching it anymore. Til it breaks 100% again. Analyst PT 75$.
0 · Reply
JdNews
JdNews Aug. 13 at 4:43 AM
$SLXN This has news by 2026. Yes it’s far off. But, it has drug that could change everything for pancreatic cancer. It’s a waiting game here. Buy the low. 7s are the low. Wait keep buying. Sometimes, a stock that has RS but has news, can run again like crazy. This is an investment waiting on news.
0 · Reply
alphaonetrading
alphaonetrading Aug. 13 at 3:20 AM
$SLXN Wait for a dip to $2.63–$4.17 to buy, as the current $7.50 price exceeds the risk-adjusted valuation. Monitor catalysts (regulatory submissions, partnerships, phase two data in 2025–2026) and prepare for dilution from the ATM. Given the 5% success probability and financial risks, allocate a small portfolio portion and set a stop-loss (e.g., 20–30% below entry)
0 · Reply
Bentradez
Bentradez Aug. 12 at 12:15 PM
$SLXN please put out a PR 🥲
0 · Reply
woolpourpis69
woolpourpis69 Aug. 11 at 11:57 AM
$SLXN scam only down.. never
0 · Reply
rosie_o
rosie_o Aug. 8 at 9:27 PM
$SLXN I assume this is glitching going up $.68 after hours. Anyone else see this?
0 · Reply
JdNews
JdNews Aug. 8 at 6:26 PM
$CYCC $ABVE $BTOG $SLXN $WBUY Do you really not know the news here and why this is going crazy since squeeze?
1 · Reply
JdNews
JdNews Aug. 8 at 6:04 PM
$SLXN Man, I know alot of you lost money here. RS suck. You should never hold thru one. But, for initial buyers at 7$ low two days ago, this is money. Analyst says 75$ PT. They have pipelines of drug here. 2026 is the year. I know that’s a ways away. Gives it time to simmer. Still low float. Not as low as before. But, waiting here on news. $CYCC
0 · Reply
JdNews
JdNews Aug. 8 at 5:51 PM
$CYCC Well. It went 10$ from that low- 7s. Buy the low sell the high. In this market, you have to. You can always get more shares after… Same with $ABVE $WBUY $SLXN $BTOG I’m in all of them. I sell the highs and buy back more shares. Until the real news hits.
3 · Reply
JdNews
JdNews Aug. 7 at 9:42 PM
$SLXN 8.60
0 · Reply
JdNews
JdNews Aug. 7 at 9:10 PM
$SLXN Went to 8.58$. Firing reg hours. This will go. You need to buy the low in 7s
1 · Reply
JdNews
JdNews Aug. 7 at 8:09 PM
$CYCC $SLXN Both up from those lows. Wouldn’t it be funny they both jump crazy. 😜 we will be partying soon
0 · Reply
JdNews
JdNews Aug. 7 at 8:06 PM
$SLXN 8.44$ so far from. 7.20s low. That’s what I was sayin
1 · Reply
JdNews
JdNews Aug. 7 at 6:25 PM
$SLXN 👀👀. Up from that low. Another one. 75$ PT, analyst here. For drugs that are showing 90% efficacy. $CYCC These 2 will go so much higher.
0 · Reply
JdNews
JdNews Aug. 7 at 5:38 PM
$CYCC $SLXN $ABVE Cycc👀👀. Hate to say I told you so
1 · Reply
Bentradez
Bentradez Aug. 7 at 2:22 PM
$SLXN madness
0 · Reply
athebeast
athebeast Aug. 7 at 11:45 AM
$SLXN To all the bulls: thanks for this gorgeous shorting opportunity. Made over 20k here 🤑🤑🤑🤑💰💰💰💰💰💰
0 · Reply
JdNews
JdNews Aug. 6 at 10:17 PM
$CYCC $SLXN Buying the low here on these 2. Waiting on big news for both. $VAPE and $ABVE Both have 1.2 trillion, in Bitcoin treasury soon enough.
0 · Reply
Orlcityfan
Orlcityfan Aug. 6 at 7:47 PM
$SLXN I went from 725 shares to 80. Then from 80 to 5 on 2 back to back reverse splits. Now they wanna increase the share amount by 525% from to 1.250m to 9m. Why do i see a wash and repeat cycle. Oh, let's add more shares to do another reverse split in a yea
1 · Reply
Yyilmaz3
Yyilmaz3 Aug. 6 at 5:14 PM
$SLXN Authorized Share Capital Increase Proposal: An increase (pursuant to an ordinary resolution) to the authorized share capital of the Company, from US$20,000 divided into 1,481,482 ordinary shares, par value US$0.0135 each, to US$121,500 divided into 9,000,000 ordinary shares, par value US$0.0135 each.
0 · Reply